{"entity":{"id":"elraglusib","kind":"drug","name":"Elraglusib","aka":["9-ING-41"],"tldr":"Elraglusib blocks a kinase that helps pancreatic cancer resist chemotherapy; in a randomised phase 2 it lengthened survival when added to gemcitabine and nab-paclitaxel, and a phase 3 is planned.","summary":"Actuate Therapeutics developed elraglusib from a series of GSK-3 beta inhibitors. In the Actuate 1801 study, part 3B randomised patients with untreated metastatic pancreatic adenocarcinoma to gemcitabine and nab-paclitaxel with or without elraglusib.\n\nThe company reported that adding elraglusib improved overall survival and one-year survival, with manageable added toxicity, mainly visual disturbance and fatigue. The result is from a phase 2 trial and awaits confirmation in a phase 3, which Actuate has said it is planning with regulators.","status":"phase-2","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT03678883","url":"https://clinicaltrials.gov/study/NCT03678883"},{"label":"Actuate Therapeutics: elraglusib programme","url":"https://www.actuatetherapeutics.com"},{"label":"Mahalingam et al., elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma, randomised phase 2 (Nature Medicine 2026)","url":"https://doi.org/10.1038/s41591-026-04327-4"},{"label":"Mahalingam et al., single-arm phase 2 (ESMO Open 2025)","url":"https://doi.org/10.1016/j.esmoop.2025.105122"}],"tags":[],"related":[],"cancers":["pancreatic","metastatic-pdac"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":["actuate-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["actuate-1801"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Randomised phase 2 (Nature Medicine 2026, 155 against 78 patients, untreated metastatic disease): median overall survival 10.1 against 7.2 months with gemcitabine plus nab-paclitaxel alone (hazard ratio 0.62, 95 percent confidence interval 0.46 to 0.84; p 0.01); one-year survival 44.1 against 22.3 percent; grade 3 or worse neutropenia 52.3 against 30.8 percent, fatigue 16.8 against 5.1 percent; the elraglusib dose was reduced to 9.3 mg/kg during the earlier single-arm phase because it exacerbated chemotherapy toxicity (ESMO Open 2025). A phase 3 is planned."],"code":"9-ING-41","modality":"Small-molecule GSK-3 beta inhibitor","mechanism":"Inhibits glycogen synthase kinase 3 beta, a kinase that drives NF-kB survival signalling and chemoresistance in pancreatic cancer and dampens anti-tumour immunity.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/elraglusib/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"company":[{"id":"actuate-therapeutics","kind":"company","name":"Actuate Therapeutics","route":"/companies/actuate-therapeutics/"}],"trial":[{"id":"actuate-1801","kind":"trial","name":"Actuate 1801 Part 3B (elraglusib)","route":"/trials/actuate-1801/"}]}}